DBC-1 Antibody (H-2): sc-166733

DBC-1 Antibody (H-2) is a mouse monoclonal IgG3 kappa light chain antibody that detects the DBC-1 protein of human origin, the 2610301G19Rik protein of mouse origin, and the corresponding rat homolog by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), and enzyme-linked immunosorbent assay (ELISA). Anti-DBC-1 antibody (H-2) is available as a non-conjugated format. DBC-1, also known as deleted in breast cancer gene 1 protein or p30 DBC protein, plays a critical role in cellular processes, particularly in the context of cancer biology. Located on chromosome 8 (8p21-8p23), DBC-1 is often found to be homozygously deleted in certain breast cancers, highlighting its importance as a tumor suppressor. DBC-1 features a nuclear localization signal, an N-terminal leucine zipper, an EF hand, and a C-terminal coiled-coil region, which are essential for its function in regulating apoptosis and cell growth. Notably, DBC-1 undergoes caspase-dependent processing during death signaling mediated by TNFα, resulting in the generation of DBC-1 p120 and p66 forms that translocate to the cytoplasm. DBC-1 p120 overexpression has been shown to induce mitochondrial clustering and enhance the sensitivity of cells to TNFα-mediated apoptosis. Furthermore, DBC-1 directly interacts with unliganded estrogen receptor alpha (ERα), stabilizing ERα expression and thereby contributing to the suppression of apoptosis and the promotion of hormone-independent cell proliferation. This multifaceted role of DBC-1 underscores its significance in cancer progression and therapeutic resistance, making DBC-1 (H-2) antibody a valuable tool for research in cancer biology and related fields.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

DBC-1 Antibody (H-2) References:

1. DBC2, a candidate for a tumor suppressor gene involved in breast cancer.  |  Hamaguchi, M., et al. 2002. Proc Natl Acad Sci U S A. 99: 13647-52. PMID: 12370419
2. Comprehensive whole genome array CGH profiling of mantle cell lymphoma model genomes.  |  de Leeuw, RJ., et al. 2004. Hum Mol Genet. 13: 1827-37. PMID: 15229187
3. Caspase-dependent processing activates the proapoptotic activity of deleted in breast cancer-1 during tumor necrosis factor-alpha-mediated death signaling.  |  Sundararajan, R., et al. 2005. Oncogene. 24: 4908-20. PMID: 15824730
4. Characterization of 8p21.3 chromosomal deletions in B-cell lymphoma: TRAIL-R1 and TRAIL-R2 as candidate dosage-dependent tumor suppressor genes.  |  Rubio-Moscardo, F., et al. 2005. Blood. 106: 3214-22. PMID: 16051735
5. Pressure stimulates breast cancer cell adhesion independently of cell cycle and apoptosis regulatory protein (CARP)-1 regulation of focal adhesion kinase.  |  Downey, C., et al. 2006. Am J Surg. 192: 631-5. PMID: 17071197
6. Large-scale identification of c-MYC-associated proteins using a combined TAP/MudPIT approach.  |  Koch, HB., et al. 2007. Cell Cycle. 6: 205-17. PMID: 17314511
7. Modulation of estrogen receptor alpha protein level and survival function by DBC-1.  |  Trauernicht, AM., et al. 2007. Mol Endocrinol. 21: 1526-36. PMID: 17473282
8. Genomic assessments of the frequent loss of heterozygosity region on 8p21.3-p22 in head and neck squamous cell carcinoma.  |  Ye, H., et al. 2007. Cancer Genet Cytogenet. 176: 100-6. PMID: 17656251
9. DBC1/CCAR2 is involved in the stabilization of androgen receptor and the progression of osteosarcoma.  |  Wagle, S., et al. 2015. Sci Rep. 5: 13144. PMID: 26249023
10. Interaction of DBC1 with polyoma small T antigen promotes its degradation and negatively regulates tumorigenesis.  |  Sarwar, Z., et al. 2022. J Biol Chem. 298: 101496. PMID: 34921839
11. SUMO1-regulated DBC1 promotes p53-dependent stress-induced apoptosis of lens epithelial cells.  |  Wang, Y., et al. 2023. Aging (Albany NY). 15: 8812-8832. PMID: 37683133
12. DBC1 maintains skeletal muscle integrity by enhancing myogenesis and preventing myofibre wasting.  |  Liang, N., et al. 2024. J Cachexia Sarcopenia Muscle. 15: 255-269. PMID: 38062876

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-DBC-1 Antibody (H-2) has 5 citations in a variety of scientific publications.

Primary antibodies like Anti-DBC-1 Antibody (H-2) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

DBC-1 Antibody (H-2) Specifications

Alternate Product Name: DBC-1

Product Clone Name: H-2

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG₃ kappa light chain

Amino Acids: 750-768

Epitope Target: DBC-1

Epitope Species: human

Product Reactivity/Detection: DBC-1 of human origin, 2610301G19Rik of mouse origin and the corresponding rat homolog

Species Reactivity/Detection: mouse, rat, human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, IHC(P), ELISA

Vialing Information: Each vial contains 200 µg IgG₃ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 5 citations in various scientific publications

Available Conjugates/Forms for DBC-1 Antibody (H-2): P: Blocking Peptide